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Over half of the estimated 50 million people with epilepsy live in Asia, but there has been limited information on the epidemiology,
aetiology and management of epilepsy from this region. In this article, we summarise some of the main problems faced by patients
and the current treatment options available in an urban area of China.
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INTRODUCTION
Hong Kong, with a population of 6.8 million, is an ur-
ban Chinese society with a long history of exposure to
the West. Traditional beliefs in epilepsy coexist with a
comprehensive modern health care system in the ter-
ritory. Over 95% of epilepsy patients are managed in
public health services, which are easily accessible and
provide universal coverage for the local population at
nominal charges. This article aims to give an overview
of the existing knowledge of epilepsy in Hong Kong
by reviewing selected studies published in both En-
glish and Chinese language journals between 1982 and
2002. The findings summarised may also have rele-
vance to the understanding of the issues surrounding
epilepsy in other major Chinese cities.
EPIDEMIOLOGY
No population-based prevalence studies have been
published in Hong Kong. Based on the figures derived
from studies conducted in other Chinese communi-
ties, where the prevalence is 3–7/1000, it is estimated
that approximately 45 000 people in this city have
active epilepsy.
The risk of recurrence after a first unprovoked and
untreated generalised tonic–clonic convulsion was
studied in 126 people1. The cumulative probability of
a second attack at 1 and 2 years were 30 and 37%,
respectively. Multivariate analysis showed that indi-
viduals with abnormal cranial computer tomography
scans had an increased risk of recurrence.
CLINICAL CHARACTERISTICS
The syndromic classification and aetiologies of
epilepsy in both adult and paediatric cohorts have
been documented in several clinic-based surveys.
The largest one conducted to date was the Hong
Kong Epilepsy Registry which identified 2952 pa-
tients with active epilepsy above the age of 10 years
from eight major public hospitals in 1997. The
commonest aetiologies were cerebrovascular dis-
ease (26.2%), a history of central nervous system
infection (26.0%), head trauma (11.4%), perinatal in-
sults (9.7%), congenital brain malformations (7.4%),
hippocampal sclerosis (5.9%) and intracranial neo-
plasms (5.6%)2. One fifth of patients had refractory
epilepsy as defined by persistent seizures despite
appropriate treatment with at least two antiepilep-
tic drugs (AEDs). Learning disability was found in
14.1% and cerebral palsy in 2.1% of patients. These
two figures were doubled in patients with refractory
epilepsy.
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In a group of patients with refractory epilepsy un-
dergoing pre-surgical evaluation, the most common
pathology demonstrated by magnetic resonance imag-
ing was mesial temporal sclerosis (41%), followed by
neocortical sclerosis (32%), vascular malformations
(10%), neuronal migration disorders (10%) and tu-
mours (7%)3.
PSYCHOSOCIAL IMPACT
Epilepsy imposes enormous psychological and social
burdens on sufferers and their families. Despite much
effort in public health education, epilepsy remains
a stigmatised condition. In a recent study of 1128
members of the general public, 32.2% would not
allow their children to marry epileptic individuals,
27.5% considered pregnancy to be inappropriate in
sufferers and 22.5% of employers would terminate
affected workers’ employment contract4. The authors
concluded that overall, public perception towards
epilepsy patients is more positive in Hong Kong than
those in Mainland China or Taiwan, but is still more
negative than in Western societies. Indeed, in a sep-
arate study, 70% of patients attributed discrimination
as the direct cause of difficulties with emotional,
interpersonal, vocational and financial adjustment
to epilepsy. Seventeen percent of the general public
thought that mutton consumption during pregnancy
would lead to epilepsy in the offspring, which is a
peculiar belief among Chinese community4.
MANAGEMENT
Pharmacological treatment
In the 1997 hospital survey, 57% patients were re-
ceiving monotherapy. The most commonly prescribed
AEDs were the established agents: 39% patients were
receiving phenytoin, 33% carbamazepine, 22% val-
proate and 11% phenobarbitone2. Of the newer drugs,
gabapentin, lamotrigine, topiramate, vigabatrin and
levetiracetam are available, for which various phase
IV studies have been conducted to evaluate their use
in the local population.
The differences in the pharmacokinetic profile of di-
azepam among Chinese and White healthy volunteers
were examined by Kumana et al.5. Although mean
peak diazepam concentration (Cmax) was similar in
both groups, mean diazepam apparent volumes of dis-
tribution were smaller and time to Cmax was prolonged
among the Chinese subjects. The authors attributed
these differences to the greater body fat and stature
in the White volunteer group. Woo et al. randomised
patients who were seizure-free but with subtherapeu-
tic serum AED levels to either continuing the same
dosage, or increasing the dosage until the therapeu-
tic range was reached6. It was found that dose incre-
ment did not lead to improvement in seizure control
but produced more neurotoxic side effects, suggest-
ing that increasing the dose in a well-stabilised patient
may not be necessary.
Non-pharmacological treatment
Epilepsy surgery is performed in a few specialist cen-
tres in Hong Kong. A small series from one centre
showed that 73% of patients with refractory epilepsy
became seizure-free after temporal lobectomy7. No
deaths or major postoperative complications occurred.
Vagal nerve stimulation was first introduced in Hong
Kong during the mid-1990s for patients with refrac-
tory partial-onset seizures who are not suitable for re-
sective surgery. Its results are also comparable to those
reported from overseas centres.
DISCUSSION
Dedicated efforts by local researchers over the past
two decades have shown that the clinical character-
istics of epilepsy patients in Hong Kong, such as
seizure types and prognosis, as well as response to
AED therapy and surgery, appear to be largely com-
parable to their Western counterparts. This finding is
important for the valid extrapolation of results gener-
ated in Europe and North America to Chinese patients
and vice versa. However, important differences, in-
cluding pharmacokinetic profiles and disease attitude,
have been observed between the two populations,
highlighting the need for locally relevant studies. To
provide essential information at the infrastructure
level, a community-based prevalence and incidence
study is currently underway in Hong Kong.
A growing number of gene mutations associated
familial epilepsy syndromes have been identified. For
the more common ‘non-hereditary’ cases, genetic
polymorphisms may play an important role in disease
susceptibility as well as response to drug treatment.
The ethnic variations in these polymorphisms should
be studied so that locally applicable pharmacoge-
netically based prescription may be realised in the
future. Knowledge gained in these areas will enable
us to improve the care of people with epilepsy both
in Hong Kong and beyond.
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